IRONWOOD PHARMACEUTICALS, INC. Available-for-sale Securities, Gross Unrealized Loss
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Available-for-sale Securities, Gross Unrealized Loss of $88.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2016-02-19
- IRONWOOD PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2015-12-31 was $81.00K, a 326.32% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2015-09-30 was -$22.00K.
- IRONWOOD PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2015-06-30 was $23.00K.
- IRONWOOD PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2015-03-31 was $6.00K, a 66.67% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for fiscal 2015 was $88.00K, a 252.00% increase from fiscal 2014.
- IRONWOOD PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for fiscal 2014 was $25.00K, a 525.00% increase from fiscal 2013.
- IRONWOOD PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for fiscal 2013 was $4.00K, a 300.00% increase from fiscal 2012.
- IRONWOOD PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for fiscal 2012 was $1.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2015-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $59.00K derived: sum of 2 quarters · filed 2016-02-19 | $82.00K derived: sum of 3 quarters · filed 2016-02-19 | $88.00K 10-K · filed 2016-02-19 |
| 2015-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $1.00K derived: sum of 2 quarters · filed 2015-11-05 | $7.00K 10-Q · filed 2015-11-05 | $26.00K derived: sum of 4 quarters · filed 2016-02-19 |
| 2015-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $29.00K 10-Q · filed 2015-08-07 | $48.00K derived: sum of 3 quarters · filed 2016-02-19 | $39.00K derived: sum of 4 quarters · filed 2016-02-19 |
| 2015-03-31 | $6.00K 10-Q · filed 2015-05-06 | $25.00K derived: sum of 2 quarters · filed 2016-02-19 | $16.00K derived: sum of 3 quarters · filed 2016-02-19 | $13.00K derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $10.00K derived: sum of 2 quarters · filed 2016-02-19 | $7.00K derived: sum of 3 quarters · filed 2016-02-19 | $25.00K 10-K · filed 2016-02-19 |
| 2014-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | -$12.00K derived: sum of 2 quarters · filed 2014-11-05 | $6.00K 10-Q · filed 2014-11-05 | |
| 2014-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $15.00K 10-Q · filed 2014-08-05 | ||
| 2014-03-31 | $18.00K 10-Q · filed 2014-04-29 | |||
| 2013-12-31 | $4.00K 10-K · filed 2015-02-18 | |||
| 2012-12-31 | $1.00K 10-K · filed 2014-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |